Jamieson Wellness Inc. Announces Filing of Management Information Circular for Annual Meeting of Shareholders

Jamieson Wellness Inc. (" Jamieson Wellness " or the " Company ") (TSX: JWEL) announced today that the Company has filed its management information circular (" Circular ") and related materials (together with the Circular, the " Meeting Materials ") for the annual meeting of shareholders (the " Shareholders ") of Jamieson Wellness to be held on May 24, 2022 at 2:00 p.m. (Eastern Daylight Time) virtually via live audio webcast at meetnow.globalMZ4D4RR (the " Meeting ").

The Meeting Materials have been filed under Jamieson's profile on SEDAR at www.sedar.com and are also available on the Company's website at www.jamiesonwellness.com .

The Meeting Materials are being mailed to Shareholders to provide information about the business to be conducted at the Meeting, detailed instructions about how to vote shares and how to attend and participate at the Meeting. The Company encourages Shareholders to review the Meeting Materials before voting their shares.

Similar to last year, to proactively address the public health impact of the COVID-19 outbreak, to mitigate the risks to the health and safety of our communities, Shareholders, employees and other stakeholders, and to comply with any applicable public health restrictions limiting indoor events that may be in effect at the time of the Meeting, the Meeting will be held in a virtual only format.

About Jamieson Wellness

Jamieson Wellness is dedicated to improving the world's health and wellness with its portfolio of innovative natural health brands. Established in 1922, Jamieson is the Company's heritage brand and Canada's #1 consumer health brand. The Company also offers a variety of natural health solutions through its Progressive, Smart Solutions, Iron Vegan and Precision brands. For more information please visit jamiesonwellness.com .

Jamieson Wellness' head office is located at 1 Adelaide Street East Suite 2200, Toronto, Ontario, Canada.

Contact

For questions or assistance with the completion and delivery of proxy materials, please contact Jamieson Wellness' proxy solicitation agent and shareholder communications advisor:

Laurel Hill Advisory Group
1.877.452.7184 toll-free in Canada
+1.416.304.0211 International
assistance@laurelhill.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

JWEL:CA
The Conversation (0)
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks in 2026

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval. However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected... Keep Reading...
Marvel Announces Final Shank3 Data: MB-204 Highly Effective at Reversing Autism Behaviours

Marvel Announces Final Shank3 Data: MB-204 Highly Effective at Reversing Autism Behaviours

Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), a drug discovery company developing novel therapeutics for autism spectrum disorder ("ASD") and related neurodevelopmental disorders, is... Keep Reading...
Medical professional's hand under a digital interface with a glowing cross and circuit design.

Eli Lilly Brings AI to Drug Delivery in METiS TechBio Deal

METiS TechBio (HKEX:7666) could collect up to US$1.1 billion in milestone payments from Eli Lilly and Company (NYSE:LLY) under a new research pact to design lipid nanoparticles that carry medicines to specific tissues in the body.Lipid nanoparticles, or LNPs, carry therapeutic payloads to target... Keep Reading...
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

briacell therapeutics corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. ("BriaPro"), today announced that four... Keep Reading...
Two people wearing lab coats shake hands in business agreement.

Telix Acquires Germany's ITM in US$1.65 Billion Deal

Melbourne-based Telix Pharmaceuticals (ASX:TLX) has agreed to acquire Germany’s ITM Isotope Technologies to secure commercial-scale radioisotope manufacturing and expand into neuroendocrine tumor treatments.The deal brings ITM’s global radioisotope production and distribution network spanning... Keep Reading...

Interactive Chart

Latest Press Releases

Related News